Array Market (Life Science and Biotechnology Instruments) to Surpass US$ 20.15 Bn by 2030

The Global Array Market (Life Science And Biotechnology Instruments), By Type (DNA Array, Protein Array, Tissue Array, Cell Array, and Others (Peptide Array and Others)) By End User (Biopharmaceutical and Pharmaceutical Companies, Diagnostic Laboratories, Research Laboratories, and Others (Academic Institutes and Others)) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 7.4 Billion in 2023 and is expected to exhibit a CAGR of 15.4% during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.

Increasing organic growth strategies, such as product launches by key market players to expand their product portfolio, are expected to drive market growth over the forecast period. For instance, in March 2020, Agilent Technologies Inc., a provider of scientific solutions, announced the launch of Agilent GenetiSure Cyto microarrays for prenatal and postnatal research. The new Agilent GenetiSure Cyto microarrays include updated, clinically relevant content from respected databases. The probes on the Cyto microarrays provide high-resolution detection of copy number variations, and copy-neutral loss of heterozygosity associated with developmental delay, neuropsychiatric disorders, intellectual disability, congenital anomalies, or unexplained dysmorphic features in constitutional DNA samples.

Similarly, in February 2020, Twist Bioscience Corporation, a biotechnology company, announced the launch of Twist Targeted Methylation Sequencing Solution to study methylation pattern changes in a wide range of research fields, including cancer. The Twist Targeted Methylation Sequencing Protocol uses the Fast Hybridization Target Enrichment workflow to generate target-enriched DNA libraries for sequencing on Illumina next-generation sequencing (NGS) systems.

Global Array Market (Life Science and Biotechnology Instruments) – Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others, faced problems with regard to the transportation of drugs from one place to another.

COVID-19 had a positive impact on the global array market (life science and biotechnology instruments), as researchers were focused on developing SARS-CoV-2 variant protein microarrays for profiling humoral immunity in vaccinated patients. For instance, in March 2022, according to the report published in the National Center for Biotechnology information, the use of a protein microarray platform to evaluate the efficacy of an inactivated virus vaccine against different variants of SARS-CoV-2 was reported. The report also stated that this platform was highly effective for profiling humoral immunity by immobilizing multiple agents.

Global Array Market (Life Science and Biotechnology Instruments): Key Developments

In July 2022, Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced the launch of Illumina DRAGEN v4.0, an accurate and comprehensive secondary analysis platform that expands laboratories abilities to perform analyses in key areas such as oncology, pharmacogenomics (PGx), single-cell sequencing, and population genomics within a single platform.

In March 2022, Sengenics, a precision medicine company, announced the launch of the i-Ome Protein Array Kit. The i-Ome Protein Array Kit contains slide-based, high-density protein microarrays comprised of 1600+ immobilized, full-length, correctly folded human proteins with KREX (a protein folding technology) technology

Similarly, in March 2022, Sengenics announced the launch of a new autoantibody profiling service, the ‘Pan-Autoimmune Protein Array 1.0’ to expedite the identification and quantitation of autoantibody disease biomarker signatures. The service is a protein microarray-based, multiplexed immunoassay that utilizes Sengenics’ KREX protein folding technology

In March 2020, Agilent Technologies Inc. announced the launch of three new microarrays to meet the needs of cytogenetic laboratories conducting both prenatal and postnatal research. Furthermore, According to the company, the GenetiSure Cyto microarrays contain current and clinically useful content from reputable sources. Additionally, using constitutional DNA samples, the microarray probes can detect copy number variations and copy-neutral loss of heterozygosity linked to developmental delays, neuropsychiatric disorders, intellectual disability, congenital anomalies, or unexplained dysmorphic features with high resolution.

Browse 43 Market Data Tables and 39 Figures spread through 247 Pages and in-depth TOC on “Global Array Market (Life Science and Biotechnology Instruments)”, By Type (DNA Array, Protein Array, Tissue Array, Cell Array, and Others (Peptide Array and Others)) By End User (Biopharmaceutical and Pharmaceutical Companies, Diagnostic Laboratories, Research Laboratories, and Others (Academic Institutes and Others)) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/array-market-life-science-and-biotechnology-instruments-4221

Key Takeaways of the Global Array Market (Life Science and Biotechnology Instruments):

• The global array market (life science and biotechnology instruments) is expected to exhibit a CAGR of 15.4% during the forecast period, owing to significant development in personalized medicines by the market players. For instance, in April 2020, Indivumed GmbH, an oncology company, announced the launch of the Oncology Alliance for Individualized Medicine, an international collaborative alliance to advance personalized medicine in cancer through IndivuType, the company’s multi-omics database.
• Among type, the DNA array segment is expected to be dominant in the global array market (life science and biotechnology instruments), owing to the increasing research and development activities, which may help in market growth over the forecast period. For instance, in April 2020, researchers from the National Defense Medical Center, Taiwan, reported the use of DNA microarray gene expression profiles in research to assess the immunofunctionomes of ovarian clear cell carcinoma in early and advanced stages.
• Among regions, North America is expected to be the dominant region in the global array market (life science and biotechnology instruments), owing to the increasing adoption of inorganic growth strategies such as collaboration and others by the market players. For instance, in April 2020, Sio Gene Therapies, a biotechnology company based in the U.S. and North America, collaborated with Invitae Corporation, a provider of advanced medical genetics, to offer free genetic testing in the U.S. and Canada for pediatric lysosomal storage disease.
• Major players operating in the global array market (life science and biotechnology instruments) include Thermo Fisher Scientific Inc., Illumina, Inc., Roche Diagnostics Nederland B.V., Bio-Rad Laboratories, Inc., Life Technologies, Caliper Life Sciences, Perkin Elmer, Inc., Siemens Healthineers, Agilent Technologies Inc., PathogenDx, Inc., Twist Bioscience Corporation, Arraylt Corporation, Molecular Device, LLC and Raybiotech Inc.